Sign In
3 May 2017 14:49
Verona Pharma plc
("Verona Pharma" or the "Company")
Block Listing Application and Review
3 May 2017, London - Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, today announces that an application has been made to the London Stock Exchange for a block listing of securities in respect of 2,183,491 ordinary shares of £0.05 each to be admitted to trading on AIM as an extension of the block listing issued in respect of ordinary shares of £0.05 each (the "Ordinary Shares") which may arise pursuant to the exercise of warrants issued in connection with the placing completed in July 2016 (the "2016 Warrant Shares") as announced on 29 July 2016.
The Company makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its block listing facility (all figures relate to Ordinary Shares in the table below):
Name of company: | Verona Pharma plc | |||
Name of scheme: | 2016 Warrant Shares | |||
Period of return: | From: | 29/07/2016 | To: | 03/05/2017 |
Number and class of securities not issued/allotted under scheme(s) from previous return (following 50/1 share consolidation announced on 08/02/2017): | 10,262,879 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 2,183,491 | |||
Less: Number of securities issued/allotted under scheme(s) during period: | 0 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 12,446,370 | |||
Number and class of share(s) (amount of stock/debit securities) originally admitted and the Date of Admission: | 10,262,879 on 29/07/2016 | |||
Total number of shares in issue at the end of the period: | 99,014,164 | |||
Name of contact: | Claire Poll |
Telephone number of contact: | +44 (0)20 3283 4200 |
Date: | 03/05/2017 |
-Ends-
For further information please contact:
|
Notes to Editors
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.
Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.
Follow the stocks
